Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2008;51:e6
Published online before print January 7, 2008, doi: 10.1161/HYPERTENSIONAHA.107.104448
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
51/2/e6    most recent
HYPERTENSIONAHA.107.104448v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Plouin, P.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Plouin, P.-F.
Related Collections
Right arrow Other hypertension
Right arrow Clinical Studies
Right arrow Other etiology

(Hypertension. 2008;51:e6.)
© 2008 American Heart Association, Inc.


Letters to the Editor

About an Epidemic of Primary Aldosteronism

Pierre-François Plouin

Assistance Publique-Hôpitaux de Paris, Hypertension Unit, Hôpital Européen Georges Pompidou, and, Faculté de Médecine, Université Paris Descartes, Paris, France


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

To The Editor:

I agree with Calhoun’s1 conclusion that there is currently an epidemic of elevated aldosterone:renin ratio rather than an epidemic of primary aldosteronism (PA). I disagree, however, with the assertion that it is "inappropriate to consider idiopathic hyperaldosteronism (presumed secondary to adrenal hyperplasia) to be a type of PA" and that PA should be confirmed by a suppression test.

According to World Health Organization’s International Classification of Disease (10th Revision, version for 2007), the E26.0 category (primary hyperaldosteronism) has 2 subheadings: Conn’s syndrome and PA because of adrenal hyperplasia (bilateral). Conn’s syndrome (or aldosterone-producing adenoma [APA]) and PA because of bilateral adrenal hyperplasia (or idiopathic PA) differ in renin and aldosterone plasma levels, renin usually being lower and aldosterone usually higher in APA than in idiopathic PA, and, theoretically, in the response to dynamic tests. Stimulation and suppression tests have been designed under the assumption that the surgically remediable form of PA, APA, is associated with angiotensin-unresponsive aldosterone hypersecretion. The predicted response to stimulation tests is a fall or no change in aldosterone concentration in cases of APA and an angiotensin-dependent rise in cases of essential hypertension or idiopathic PA. However, several studies reported that 30% to 70% of patients with APA display an increase in aldosterone levels with ambulation. Stimulation tests do not help identify subjects with PA and an APA,2 a lateralized aldosterone hypersecretion on adrenal venous sampling,2 or a favorable BP outcome after surgery.2 Many suppression tests have been proposed for the confirmation of PA . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
HypertensionHome page
J. Matrozova, O. Steichen, F. de Medecine, and P.-F. Plouin
Response to Metabolic Dysfunction in Primary Aldosteronism
Hypertension, June 1, 2009; 53(6): e38 - e38.
[Full Text] [PDF]


Home page
HypertensionHome page
D. A. Calhoun
Response to About an Epidemic of Primary Aldosteronism
Hypertension, February 1, 2008; 51(2): e7 - e7.
[Full Text] [PDF]